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Many cancer patients develop resistance to chemothera-
peutic drugs and this results in elevated mortality.
Understanding the mechanisms that mediate drug
resistance is critical to develop novel therapeutic strate-
gies. Fibroblast growth factor (FGF)-2, which leads to
the formation of a B-RAF/PKCε/S6K2 multi-protein
complex, plays a key role in chemoresistance. This
enhances the selective translation of anti-apoptotic pro-
teins such as BCL-2 and IAP family members and
protects cells from death induced by chemotherapy in
several cancer types. We have been investigating the
role of Janus kinases (JAKs) and signal transducers and
activators of transcription (STATs), most notably known
for their pivotal roles in mediating cytokine and
immune responses, in FGF-2-mediated chemoresistance.
The participation of JAKs in drug resistance pathways
and the implications of using inhibitors to these kinases
in cancer multi-target therapies will be discussed.
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